BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $16.03 billion. The enterprise value is $17.58 billion.
| Market Cap | 16.03B |
| Enterprise Value | 17.58B |
Important Dates
The next confirmed earnings date is Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 195.49 million shares outstanding. The number of shares has increased by 1.99% in one year.
| Current Share Class | 195.49M |
| Shares Outstanding | 195.49M |
| Shares Change (YoY) | +1.99% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 86.39% |
| Owned by Institutions (%) | 81.29% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.64 |
| Forward PS | 14.91 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 30.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52
| Current Ratio | 1.52 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.78 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.98% |
| Return on Invested Capital (ROIC) | -142.30% |
| Return on Capital Employed (ROCE) | -94.66% |
| Weighted Average Cost of Capital (WACC) | 9.16% |
| Revenue Per Employee | $691,249 |
| Profits Per Employee | -$860,014 |
| Employee Count | 839 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.53 |
Taxes
In the past 12 months, BBIO has paid $435,000 in taxes.
| Income Tax | 435,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.71% in the last 52 weeks. The beta is 0.98, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +71.71% |
| 50-Day Moving Average | 74.85 |
| 200-Day Moving Average | 71.76 |
| Relative Strength Index (RSI) | 55.40 |
| Average Volume (20 Days) | 3,197,009 |
Short Selling Information
The latest short interest is 25.75 million, so 13.17% of the outstanding shares have been sold short.
| Short Interest | 25.75M |
| Short Previous Month | 24.10M |
| Short % of Shares Out | 13.17% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.11 |
Income Statement
In the last 12 months, BBIO had revenue of $579.96 million and -$721.55 million in losses. Loss per share was -$3.74.
| Revenue | 579.96M |
| Gross Profit | 551.70M |
| Operating Income | -504.22M |
| Pretax Income | -729.45M |
| Net Income | -721.55M |
| EBITDA | -519.66M |
| EBIT | -525.00M |
| Loss Per Share | -$3.74 |
Balance Sheet
The company has $940.19 million in cash and $2.49 billion in debt, with a net cash position of -$1.55 billion or -$7.94 per share.
| Cash & Cash Equivalents | 940.19M |
| Total Debt | 2.49B |
| Net Cash | -1.55B |
| Net Cash Per Share | -$7.94 |
| Equity (Book Value) | -2.27B |
| Book Value Per Share | -11.64 |
| Working Capital | 424.93M |
Cash Flow
In the last 12 months, operating cash flow was -$443.95 million and capital expenditures -$1.17 million, giving a free cash flow of -$445.12 million.
| Operating Cash Flow | -443.95M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 5.34M |
| Net Borrowing | 932.50M |
| Free Cash Flow | -445.12M |
| FCF Per Share | -$2.28 |
Margins
Gross margin is 95.13%, with operating and profit margins of -86.94% and -124.41%.
| Gross Margin | 95.13% |
| Operating Margin | -86.94% |
| Pretax Margin | -125.78% |
| Profit Margin | -124.41% |
| EBITDA Margin | -89.60% |
| EBIT Margin | -90.52% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.99% |
| Shareholder Yield | -1.99% |
| Earnings Yield | -4.50% |
| FCF Yield | -2.78% |
Analyst Forecast
The average price target for BBIO is $105.26, which is 28.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $105.26 |
| Price Target Difference | 28.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 69.82% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -2.72 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.72 |
| Piotroski F-Score | 2 |